Uploaded August 2025 | Updated September 2026, 2 weeks ago
Indian Pharma has built its strength on scale, affordability, and scientific depth, making critical treatments, from generics to biosimilars, accessible to millions worldwide. The industry continues to face headwinds, from regulatory scrutiny and US tariff pressures to the impact of AI on drug discovery. Yet its role in the global healthcare system remains central. As India shifts from being the “pharmacy of the world” to an innovation-led ecosystem, the next phase will be defined by how effectively pharma companies integrate R&D, policy, and manufacturing to compete globally while serving domestic needs. An inspiring session with Ashish kumar, Senior Vice President & Cluster Head, Zydus Group, as he shares:
* How Indian Pharma transformed global drug access
* The role of biosimilars & generics in healthcare equity
* What lies ahead in innovation and global growth
Indian Pharma has built its strength on scale, affordability, and scientific depth, making critical treatments, from generics to biosimilars, accessible to millions worldwide. The industry continues to face headwinds, from regulatory scrutiny and US tariff pressures to the impact of AI on drug discovery. Yet its role in the global healthcare system remains central. As India shifts from being the “pharmacy of the world” to an innovation-led ecosystem, the next phase will be defined by how effectively pharma companies integrate R&D, policy, and manufacturing to compete globally while serving domestic needs. An inspiring session with Ashish kumar, Senior Vice President & Cluster Head, Zydus Group, as he shares:
* How Indian Pharma transformed global drug access
* The role of biosimilars & generics in healthcare equity
* What lies ahead in innovation and global growth
